Drugs / Tegafur/Uracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00384800 | Sep 2006 → ? | hepatocellular carcinoma | Far Eastern Memorial Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tegafur/Uracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00384800 ↗ |
| Known as | UFT | “UFUR® is a composite drug composed of 100mg tegafur and 224mg uracil (molar ratio:1:4). It was marketed as UFT® in Japan and marketed as UFUR® in Taiwan.” NCT00384800 ↗ |
| Known as | UFUR | “Thalidomide(THADO), Tegafur/Uracil(UFUR)” NCT00384800 ↗ |
| Route | Oral | “Both drugs are orally active, thus are convenient to be given on an out-patient basis.” NCT00384800 ↗ |